EGFR and breast cancer: Previous studies on AuNPs synthesized with quercetin as reducing agent (Qc–AuNPs) revealed that Qc–AuNPs inhibit the epithelial–mesenchymal transition, angiogenesis, and invasiveness via epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR)-2-mediated pathway and induce apoptosis via inhibiting EGFR/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)-mediated pathway in breast cancer cell lines (MCF-7 and MDA-MB 231) [22,23].